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Abstract 
Utility measures of health-related quality of life 
are preference values that patients attach to their 
overall health status. In clinical trials, utility mea- 
sures summarize both positive and negative effects 
of an intervention into one single value between 0 
(equal to death) and 1 (equal to perfect health). 
These measures allow for comparison ofpatient out- 
comes of different diseases and allow for comparison 
between various health care interventions. There are 
two different approaches to utility measurement. 
The first is to classify patients into categories based 
on their responses to a number of questions about 
their functional status, as for instance the Quality of 
Well-Being questionnaire. The second approach is to 
ask patients to assign a single rating to their overall 
health by means of rating scale, standard gamble, 
time trade-off; or willingness to pay. The Quality 
Adjusted Life Year (QALY) as outcome measure 
includes both effects in terms of quality and quantity 
of life. Utilities are used as weights to adjust life 
years for the quality of life in order to calculate 
QALYs. Both QALYs and utilities are useful in 
decision-making regarding appropriate procedures 
for groups of patients. 
Key words: Utility measurement; Quality 
adjusted life years; Rheumatology. 
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Introduction 
Quality of life may be affected by rheumatic 
diseases. In fact, quality of life is a broad con- 
cept of multiple viewpoints and includes all 
factors that impact upon an individual’s life. 
Health-related quality of life includes only 
those factors that are part of an individual’s 
health, which can be defined according to the 
World Health Organization as a state of com- 
plete physical, mental and social well-being 
(WHO, 1958). 
Recognition of the impact of chronic 
diseases on the patient and the desirability to 
evaluate treatment effects has led to the de- 
velopment of instruments that measure quali- 
ty of life. Health-related quality of life 
instruments commonly used in rheumatology 
usually assess pain, stiffness and physical mo- 
bility. However, these instruments are speci- 
fic, as they aim at a specific disease (e.g. 
ankylosing spondylitis), or at a specific popu- 
lation of patients (e.g. rheumatic patients). 
The rationale for specific instruments lies in 
its potential for increased responsiveness, 
because only those aspects of quality of life 
are included for which a priori change can be 
expected. The disadvantage is that they can- 
not be used for comparisons between different 
Ltd. 
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patient populations, which is possible with 
more generic instruments. Generic instru- 
ments are applicable in a wide variety of 
populations because they cover a broad spec- 
trum of aspects relative to quality of life. 
Guyatt et al. (1989) distinguishes two major 
subcategories of generic instruments: health 
profiles and utility measures. Using health 
profiles, scores of separate items are obtained 
which can be combined in a few subdimen- 
sional scores and sometimes into one single 
index score. An example of a health profile is 
the Sickness Impact Profile (SIP) (Bergner et 
al., 1981) which measures physical, mental, 
emotional and social aspects of function. 
Utility Measurement 
Utility measures of health-related quality of 
life are single measures of the value or prefer- 
ence that the respondents attach to their 
overall health status. Respondents can be the 
general public, health care providers or pa- 
tients. In health care decision-making it 
would be very advantageous to have such a 
single numerical measure that really reflects 
the value of the overall health improvement. 
It would be useful in making decisions about 
treatments for individual patients (clinical 
decision-analysis) and decisions regarding ap- 
propriate procedures and technology for 
groups of patients (technology assessment) 
(Torrance and Feeny, 1989). 
In this article we will discuss patient utilities 
as a measure of effect in evaluating 
treatments. In our clinical trials we have 
chosen to measure patient utilities since they 
reflect the relative value of different health 
states to people we believe should benefit 
from services provided by the health care sys- 
tem (Mehrez and Gafni, 1989). In clinical tri- 
als, utility measures can be valuable because 
patients combine positive and negative effects 
of an intervention into one single value be- 
tween 0 (equal to death) and 1 (equal to 
perfect health). With commonly used generic 
and specific instruments these positive and 
negative effects are measured separately, and 
the investigator has little or no information 
on the patient’s trade-offs among therapeutic 
improvements and treatment side effects. 
Measurement of health-related utility 
There are two approaches to utility mea- 
surement (Bell et al., 1990). Thefirst approach 
is to classify patients into categories based on 
their responses to questions about their func- 
tional status. In the Quality of Well-Being 
(QWB), formerly called the Index of Well- 
Being, this approach is used. Patients are to 
complete a questionnaire on their perfor- 
mance within three dimensions: mobility, 
physical and social activity. Each dimension 
consists of live, four and live levels of perfor- 
mance, respectively. Patients are thus 
classified into one of the 43 possible combina- 
tions of levels. Each combination of levels 
describes a unique health state. Each health 
state and a standard list of symptoms and pro- 
blems have already been valued by the general 
public and by patients with rheumatoid ar- 
thritis by means of a categorical rating from 0, 
equal to “as bad as dying”, to 1, equal to 
“completely well” (Balaban et al., 1986). 
These ratings are used as values assigned to 
each health state into which the patient (re- 
sponding to the QWB questionnaire), is 
classified. The values are then modified by the 
presence or absence of problems and symp- 
toms of the standard list. They are added to 
establish an overall QWB value ranging from 
0 (dead) to 1 (healthy). 
The second approach to utility measurement 
is to ask patients directly to assign one value 
to their overall health. The four methods 
which are most frequently used to elicit utility 
values are rating scale, standard gamble, time 
trade-off and willingness to pay. 
A rating scale consists of a line on paper 
with clearly defined end points or anchors. It 
requires that the patient identifies the most 
and least preferred health states to use as 
anchor, usually labeled as “perfect health” 
and as “death”. Then the patient is asked to 
place in order of preference his own health 
state and so-called marker health states on the 
rating scale between these anchors; such that 
the intervals between the placements reflect 
the differences the patient experiences be- 
tween the health states. A useful visual aid for 
the rating scale is a large ‘thermometer’ with 
a scale from 0 to 100 (Fig. 1). 
The standard gamble technique is based 
directly on the Von Neumann-Morgenstern 
Fig. 1. The rating scale, a thermometer. 
mild marker state 
own health state 
severe marker state 
utility theory and is the original method of 
measuring utilities (Von Neumann and 
Morgenstern, 1944). The standard gamble 
method consists of paired comparison in 
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which the patient must choose between two 
alternatives. Alternative 1 is a choice with two 
outcomes: either a good outcome, i.e. living in 
perfect health, with probability P; or a bad 
outcome, i.e. dying, with probability 1 - P. 
Alternative 2 has one outcome which is inter- 
mediate in desirability between the good and 
bad outcomes of Alternative 1, as for instance 
the patient’s current health state. Probability 
P is varied until the patient is indifferent to 
the two alternatives. At this point the required 
utility for the patient’s health state has been 
obtained. It is assumed that patients with a 
better health accept less risk in order to im- 
prove than the more severely affected patients 
(Torrance, 1987). The standard gamble is sup- 
plemented by the use of a probability wheel. 
The time trade-off method is an implicit 
technique like the standard gamble, but it 
does not include risks. Both methods implicit- 
ly deduce utilities from the patients’ responses 
to decision situations, whereas in the rating 
scale method, the preference values are ex- 
plicitly provided by the patient (Torrance, 
1987). The time trade-off is also a paired com- 
parison in which the patient must choose be- 
tween two alternatives. Alternative 1 is to 
maintain the patient’s health state for the rest 
of their life (time t), while the other alternative 
is a shorter (time x) but healthy life. Time x is 
varied until the patient is indifferent to the 
two alternatives, at this point the required 
preference value for the patient’s health state 
is x/t. It is assumed that the less desirable the 
patient’s health state, the larger the amount of 
lifetime (in years or months) the patient will 
trade-off in order to be free from his health 
state (Torrance, 1987). Usually a visual aid is 
also used with this technique. 
By means of the willingness to pay question- 
naire, patients are asked how much money 
they are willing to pay for a hypothetical cure. 
Thompson (1986) reported that rheumatoid 
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arthritis patients were willing to pay 22% of 
their household income for a complete cure of 
their arthritis. 
These four methods of measuring health- 
related utility are not interchangeable, 
because they are based on different assump- 
tions and do not all include the risk com- 
ponent. 
Patient utilities published in the literature 
In the field of rheumatology, only one 
published randomized controlled drug trial 
used utility measures. Bombardier et al. 
(1986) reported the results of a multicenter 
trial in which auranofin (oral gold) was com- 
pared with placebo in the treatment of pa- 
tients with rheumatoid arthritis. Outcome 
assessment included clinical measures (e.g. 
number of tender joints and erythrocyte sedi- 
mentation rate) and quality of life measures. 
The last set of measures included arthritis- 
specific instruments (e.g. Health Assessment 
Questionnaire (HAQ)) as well as generic in- 
struments (e.g. Quality of Well-Being Ques- 
tionnaire (QWB) and Patient Utility 
Measurement Set (PUMS)). Like the clinical 
measures, the arthritis-specific quality of life 
scales showed significant improvement of the 
auranofin group compared to the placebo 
group. At the same time the auranofin group 
reported more side effects. By means of an 
overall assessment as reflected in the utility 
score (PUMS and QWB), positive and nega- 
tive effects of treatment were balanced. In the 
patient’s opinion functional improvements 
were superior to injurious side effects because 
the PUMS as well as the QWB showed a signi- 
ficant improvement of auranofin in com- 
parison to placebo. 
Maastricht Utility Measurement questionnaire 
As an example of an utility measurement 
instrument we will now describe the 
Maastricht Utility Measurement question- 
naire. By means of this questionnaire we have 
elicited utility values from patients with 
ankylosing spondylitis or tibromyalgia (un- 
published data). 
The Maastricht Utility Measurement ques- 
tionnaire, a Dutch translation and adaptation 
of the McMaster Utility Measurement ques- 
tionnaire (Bennett et al., 1991), will be ex- 
plained by the next three steps: (1) definition 
of health, (2) description of health states and 
(3) valuation of health states. 
Definition of health. Various authors use 
various dimensions to define the concept of 
health. In the Maastricht Utility Measure- 
ment questionnaire health has been defined 
by six dimensions: (1) activities of daily living, 
(2) self-care functions, (3) emotional func- 
tions, (4) leisure activities, (5) pain, and (6) 
side-effects of treatment. Each dimension con- 
sists of five levels of severity: Level 1 reflects 
the best situation and level five the worst 
(Table 1 shows the backtranslation of the di- 
mensions and its levels of the Maastricht 
Utility Measurement questionnaire). 
Description of health states. The combina- 
tion of the levels indicated by the patient in 
the interview, one for each dimension, was 
used to define ‘patient’s own health state’. 
Marker states were created by the combina- 
tion of six levels, one for each dimension. 
Perfect health was described by combining the 
first levels of all six dimensions, a severe 
marker state was described by combining the 
fifth level of all six dimensions. Also a mild 
and moderate marker state were described by 
a combination of six levels (Table 2 shows the 
description of the mild marker state). These 
marker states are valuable during the mea- 
surement process, as they encourage the re- 
spondent to consider a broad range of 
possibilities before determining their own 
health state on the spectrum of possibilities 
(Torrance and Feeny, 1989). 
Valuation of health states. The measurement 
of utilities is performed using rating scale and 
standard gamble technique. After patients 
have read the description of the marker states 
and described their health state, they are first- 
ly asked to rank and value the health states by 
means of a rating scale, a thermometer with 
perfect health equal to 100 at the top and a se- 
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Table 1. Backtranslation of the six dimensions of 
health (Roman numeral) and its levels. 
I. General Daily Activities and Mobility 
Think of limitations caused by tiredness, tightness of 
the chest or pain while working, doing the housework, 
shopping, walking, climbing stairs, using public transport, 






Able to perform all daily activities and duties at a 
normal level of mobility 
Able to perform daily activities, but with some dif- 
ficulties 
Limited in the performance of daily activities 
Limited considerably in the performance of daily ac- 
tivities 
Unable or hardly able to perform daily activities 
II. Personal Care 
Think of e.g. eating, washing, taking a shower or a bath, 







Completely capable to perform all self-care activities 
Now and then having difficulty in the performance 
of self-care activities 
Having difficulty in the performance of self-care ac- 
tivities 
Considerable difficulty in performing self-care 
activities 
Help needed for all self-care activities 
Anxieties, Frustrations and Worries Related to the 







No anxieties, no worries, not concerned about the 
course of the disease 
Normally no anxieties, sometimes concerned about 
the course of the disease 
Depressed because of the inability to function 
normally 
Often anxious, often concerned about the course of 
the disease 
Depressive, unhappy and frustrated 
Leisure Activities 







Able to participate in all leisure activities without dif- 
ficulty 
Able to participate in all leisure activities but with 
some difficulty 
Ability to participate in leisure activities is limited 
No longer able to participate in any leisure activity 
which requires a certain degree of physical effort or 
mobility 
Not able to participate in any leisure activity 
V. Pain 
(1) No pain 
(2) Occasionally pain 
(3) Often mild to moderate pain 
(4) Often severe pain 
(5) Continuously severe pain 
VI. Side Effects of Treatment 
Think of e.g. nausea, vomiting and/or diarrhoea, GI 
upset, skin rash, mouth ulcers. 
(1) No side effects 
(2) Occasionally mild side effects 
(3) Occasionally moderate - severe side effects 
(4) Often moderate - severe side effects 
(5) Severe side effects 
vere marker state equal to 0 at the bottom 
(Fig. 1). In addition, the thermometer gives 
the patient the opportunity to become 
familiar with the states and gives the in- 
vestigator an indication of the ordinal rank- 
ings of the health states and information on 
the intensity of those preferences. Next, the 
standard gamble technique is performed with 
a probability wheel as a probe. In the stan- 
dard gamble method, the health states are 
valued under risk, as opposed to under cer- 
tainty as in the rating scale method. 
In patient utility measurement, patients are 
usually asked how they value their own health 
state in comparison to perfect health and 
death (Fig. 2a). However, in rheumatic 
diseases with rather low disease-related mor- 
tality direct confrontation with the risk of 
dying may be inappropriate in a preference 
Table 2. Description of the mild marker state. 
0 Able to perform all daily activities and duties at a 
normal level of mobility 
?? Completely capable to perform all self-care activities 
?? Normally no anxieties, sometimes concerned about 
the course of the disease 
0 Ability to participate in leisure activities is limited 
0 Occasionally pain 
0 Occasionally mild side effects 
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Fig. 2. (a) Standard Gamble: Value your own 
health state in comparison to perfect health and 
death. (b) Two-Step Standard Gamble: First Step, 
Value your own health state in comparison to 
perfect health and the severe marker state. (c) TWW 
Step Standard Gamble: Second Step, Value your 




I Perfect hea’th 
3 Alter nst ive 2 ’ probabi’itv ’ - ’ ~~~~ea,th State 
probability P 
state 
assessment exercise. Therefore a two-step 
utility assessment is suggested. The patients 
are first asked to value their own health state 
in comparison to perfect health and the severe 
marker state (Fig. 2b), and then to value the 
severe marker state in comparison to perfect 
health and death (Fig. 2c), which gives a utili- 
ty value for the severe marker state. Utility 
values for the patient’s own health state can 
be calculated by using the results of these two- 
steps of the standard gamble (Drummond et 
al., 1987). 
At follow-up visits it is also possible to ask 
the patients to compare their health state at 
baseline with their health state at follow-up. 
This additional question enables the patient 
to directly express the change in health- 
related quality of life in a utility value. 
To illustrate the method of standard gam- 
ble questions that we ask patients, we now 
present a series of choices. Imagine you are a 
fibromyalgia patient and to find out how you 
value your health state at this moment, the 
first set of alternatives is: Alternative A: 100% 
chance of living perfectly healthy and 0% 
chance of living like the severe marker state. 
Alternative B: living in your current health 
state (suppose you have fibromyalgia). All 
health states sustain for the rest of your life. 
We assume you choose Alternative A. The 
next set is: Alternative A: 10% chance of liv- 
ing perfectly healthy and 90% chance of living 
like the severe marker state. Alternative B re- 
mains the same. We assume your tibromyalgia 
is not that bad that you take such a big risk 
and choose Alternative B. Then we continue 
with the next set: Alternative A: 90% chance 
of living perfectly healthy and 10% chance of 
living like the severe marker state. Alternative 
B remains the same. If you feel not that bad, 
you probably will not take the risk and 
therefore choose your own health state, the 
standard gamble stops and this last choice is 
reported. If you feel your fibromyalgia is that 
bad that you would take the risk, we continue 
to the next set: 20% chance of living perfectly 
healthy and 80% of living like the severe 
marker state. If you choose Alternative B, the 
next set of chances is 80% chance of living 
perfectly healthy and 20% of living like the se- 
vere marker state. If you choose A, the next 
set is 30% chance of living perfectly healthy 
and 70% of living like the severe marker state, 
et cetera. This is the first step of the two-step 
standard gamble question as presented in Fig. 
3b. 
Quality Adjusted Life Years 
Quality of life measurements are often used 
in studies of interventions in rheumatic 
diseases, because these interventions are pri- 
marily directed towards the prevention or re- 
duction of morbidity rather than mortality. 
Most interventions in rheumatology have no 
effect on survival, but do affect quality of life. 
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These effects can be positive as well as nega- 
tive. Assigning utilities to intervention- 
induced changes in quality of life is a way to 
balance effects of different sizes, both positive 
and negative, and combine them in an overall 
summary value. Furthermore, using utilities 
as outcome measures allows not only a com- 
parison of different interventions in rheuma- 
tic diseases, but also a comparison between 
these interventions and interventions in non- 
rheumatic diseases which also aim at improv- 
ing the quality of life. 
Besides interventions primarily directed at 
improving the quality of life, a number of 
health care interventions affect life expectan- 
cy. Moreover, a number of health care in- 
terventions do affect both the quality and 
quantity of life. To allow the comparison of 
the effectiveness between these various in- 
terventions, an additional outcome measure, 
the so-called Quality Adjusted Life Year 
(QALY) has been introduced. 
A QALY, a concept which was first in- 
troduced by Weinstein (Weinstein and 
Stasson, 1977) is a single comprehensive out- 
come measure that includes effects in terms of 
both quality of life and survival. Suppose, for 
example, that the quality of life of an individ- 
ual patient suffering from ankylosing spon- 
dylitis improves from 0.70 to 0.79 by effective 
drug therapy. This improvement will last for 
the remaining lifetime of 25 years. Suppose 
the survival of a patient who has had a trans- 
plant heart increases by 2 years at a quality of 
0.8 and an additional half year at a quality of 
0.6. This patient gains (2 x 0.8) + 
(0.5 x 0.6) = 1.9 QALYs, whereas the 
ankylosing spondylitis patient gains 
25 x (0.79 - 0.70) = 2.25 QALYs. 
In calculating QALYs, the remaining life 
years are weighted by using a quality-index 
for the patients’ health state during these 
years. These weights can be elicited by perfor- 
ming utility measurement. Utilities are not the 
same as QALYs but are used as weights to ad- 
just life years for the quality of life in order to 
calculate QALYs (Torrance and Feeny, 
1989). 
Both utilities and QALYs can be related to 
costs, resulting in a cost-utility analysis, which 
is useful to planners and policy makers. 
QALYs have the potential advantage over 
utilities that the meaning of costs per unit of 
utility gained may not have the intuitively ap- 
pealing meaning as costs per QALY gained. 
However, there are still a number of pro- 
blems. Our aim is not to discuss them exten- 
sively, but to mention some of them. A major 
problem is the assumed independence be- 
tween life years and quality of life which 
allows the direct multiplication of life years 
with utilities. However, it is likely that the 
utility that an ankylosing spondylitis patient 
assigns to living with moderate ankylosing 
spondylitis will not only be determined by this 
particular health state, but also by the number 
of years this health state is expected to last. 
For a possible solution to this problem see 
Mehrez and Gafni (1989) and Gafni (1989). 
Another problem concerns the com- 
parability of utilities and QALYs across dif- 
ferent interventions. A comparison is not 
allowed when QALYs are not based on the 
same underlying methods of utility measure- 
ment (rating scale, standard gamble, time 
trade-off) which in turn have to be based on 
the same underlying dimensions of health. It 
is shown that different methods of utility mea- 
surement do produce essentially different re- 
sults (Read et al., 1984). And who is to judge 
which dimensions are the right ones? Dimen- 
sions used in various utility measurement in- 
struments so far may not be as sensitive to 
changes in chronic conditions as they are to 
changes achieved by acute care (Donaldson et 
al., 1988). This raises criticism concerning the 
consequences of using QALYs for the distri- 
bution of health care resources (Smith, 1987; 
Loomes and McKenzie, 1989). 
QALYs are originally developed in the con- 
text of cost-utility analysis, thus allowing a 
broad comparison of interventions across 
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disease categories. Despite a number of pro- 
blems which still have to be solved, the utility 
and QALY-approach will become more 
useful as more and more interventions are 
analyzed using the same underlying health di- 
mensions and the same underlying methods 
for obtaining the utilities. By means of utility 
measurement, value judgement which other- 
wise implicitly guides decisions about the dis- 
tribution of health care technologies is now 
made explicit. This has at least the potential 
to increase rationality in decision-making. 
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